Dyne Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing life-transforming therapies for patients with serious muscle diseases.
The company’s proprietary FORCE™ platform is designed to deliver targeted therapies to muscle tissue, addressing the underlying genetic causes of debilitating diseases such as Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1), and facioscapulohumeral muscular dystrophy (FSHD).
By leveraging its precision delivery platform, Dyne Therapeutics aims to develop therapies that have higher efficacy, lower toxicity, and better patient outcomes compared to traditional approaches. The company’s growth strategy revolves around advancing its pipeline of therapeutic candidates through clinical trials and expanding the application of its FORCE™ platform across multiple indications.
With a focus on innovation and a commitment to improving the lives of patients with genetic muscle disorders, Dyne Therapeutics is well-positioned to make a significant impact in the field of precision medicine.
